Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Project Grant

University of British Columbia

$883,575.00

Dominant genetics of cohesin pathway proteins to kill cancer

FY 2022-23

Summary
Cancer cells make a lot of mistakes as they divide and grow. This allows them to accumulate mutations in their DNA which can fuel cancer development. However, sloppy maintenance of their DNA also makes cancer cells vulnerable to therapies which attack this mechanism. Unfortunately only a handful of such therapies exist, making it difficult for clinicians to apply targeted or personalized approaches in this setting. We are studying a group of proteins involved in holding chromosomes together called cohesins that work to maintain a stable genome, and therefore could be good targets for cancer therapy. We will create models in the lab that can better represent what would happen if we had specific cohesin targeting drugs. Then we will use this knowledge to help identify which specific patients could benefit from such drugs. Our models can also tell us where and how new drugs might work to inhibit cohesin proteins, fueling future drug discovery efforts. Overall, this project will open up new prospects for cancer patients with an increased toolbox for therapeutic target identification and validation.
Program
Project Grant
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
468785
Name
Stirling Peter C
Region
British Columbia
Country
Canada
Orgtype
Research Institution; Institution Paid
Instname2
Genetics
Theme2
Biomedical
Prcname2
Biochemistry & Molecular Biology - B
Projecttitle
Dominant genetics of cohesin pathway proteins to kill cancer
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$883,575
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Dominant Genetics; Genome Instability; Missense Mutations; Mutational Scanning; Protein Trapping; Smc Atpases; Synthetic Lethality
Abstract
Cancer cells make a lot of mistakes as they divide and grow. This allows them to accumulate mutations in their DNA which can fuel cancer development. However, sloppy maintenance of their DNA also makes cancer cells vulnerable to therapies which attack this mechanism. Unfortunately only a handful of such therapies exist, making it difficult for clinicians to apply targeted or personalized approaches in this setting. We are studying a group of proteins involved in holding chromosomes together called cohesins that work to maintain a stable genome, and therefore could be good targets for cancer therapy. We will create models in the lab that can better represent what would happen if we had specific cohesin targeting drugs. Then we will use this knowledge to help identify which specific patients could benefit from such drugs. Our models can also tell us where and how new drugs might work to inhibit cohesin proteins, fueling future drug discovery efforts. Overall, this project will open up new prospects for cancer patients with an increased toolbox for therapeutic target identification and validation.
Competitiondate
202209
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Stirling, Peter C
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $883,575~ $0~